Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I crossover bioavailability and food-effect study of pediatric TMC278 formulations in healthy adults
NL-OMON32773Phase 1Active, not recruiting
- Sponsor
- Tibotec
- Start
- Jan 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of rilpivirine in human immunodeficiency virus infection (HIV) (4 arms), sponsored by Tibotec. Primary endpoints: Relative oral bioavailability of pediatric formulations versus adult tablet and Food effect on pediatric formulations. Started Jan 2009; status: active, not recruiting.
02
Drugs
rilpivirine
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NL-OMON32773.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON32773.